Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
JAMA Network Open|July 14, 2026
Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical CancerAlberto Farolfi, Chiara Casadei, Emanuela Scarpi, et al.Diagnostics (Basel, Switzerland)|August 14, 2020
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World ExperienceMichela Palleschi, Roberta Maltoni, Sara Ravaioli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB studyValentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Giancarlo Bisagni, Federico Piacentini, et al.Breast (Edinburgh, Scotland)|July 7, 2026
Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysisAndrea Carlini, Flavia Foca, Marianna Sirico, et al.JAMA Oncology|February 13, 2025
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical TrialMaria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, et al.Molecular Cancer|April 30, 2017
The landscape of BRAF transcript and protein variants in human cancerAndrea Marranci, Zhijie Jiang, Marianna Vitiello, et al.The Oncologist|May 8, 2025
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variantsMichela Palleschi, Alessandra Virga, Emanuela Scarpi, et al.BMC Cancer|June 15, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER studyFabio Canino, Monica Barbolini, Ugo De Giorgi, et al.BMC Medicine|November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.Pageof 5